Philip 2007 Salm 50.

Methods	Study design: Randomized, double blind, cross over Study location: South America Wash‐out: 3‐7 days Exercise challenge: Treadmill for 6 min up to 80‐90% of max HR Criteria for EIB diagnosis: FEV1 fall >20% and <40% after exercise challenge
Participants	Number of subjects:47 % of males: 49% Age range: 15‐45 years Ethnicity: 55% Caucasian; 45% Others Withdrawal or drop out: 1
Interventions	Drug administration: Single dose Time of exercise challenge after drug administration: 2 hours, 8.30 hours, 24 hours Intervention: Salmeterol 50 mcg Control: Placebo Other drug arms: Oral Montelukast 10 mg Concomitant inhaled corticosteroid (ICS) treatment: Allowed
Outcomes	Primary available: Max FEV1 % fall; % protection Secondary available: Side effects
Notes	Industry funded study
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomization described explicitly
Allocation concealment (selection bias)	Unclear risk	Insufficient information
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double blind study
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information
Selective reporting (reporting bias)	Unclear risk	Insufficient information
Other bias	Unclear risk	Insufficient information